Complex treatment method of ulcer-erosion injure in gastroduodenal region combining with arterial hypertension

FIELD: medicine, cardiology, gastroenterology.

SUBSTANCE: invention relates to a method for treatment of ulcer-erosion injures in gastroduodenal region in patients with arterial hypertension. Method involves detection of immune disturbances and carrying out the combined immunomodulating therapy and hypotensive therapy. Immunocorrecting complex consists of licopide, cortexinum, vetoronum TK in arterial hypertension of I-II degree and comprises superlymph additionally in arterial hypertension of III degree. Method provides attaining optimal results in treatment for relatively short time due to adequate immunocorrection in such patients.

EFFECT: improved method for treatment.

5 cl, 6 tbl, 2 ex

 

The invention relates to medicine, namely to gastroenterology, immunology and cardiology.

Ulcer and erosive lesions of the gastroduodenal zone (EAEPGZ) is a multifactorial systemic diseases whose development significant role belongs to the state of the protective forces of the body and above all, its immune status. Determination of immune status changes is very important in these patients, especially with frequent relapses, adverse vnesnetorgovih factors and the lack of effectiveness of the treatment.

According to the authors, in 33% of cases EAEPGZ combined with arterial hypertension (AH), which is the most common pathology of the cardiovascular system. This combination adversely affects the development of both diseases and dictates the need for improved therapeutic and preventive measures with regard to the work of the immune system in these patients.

As a prototype the authors suggest that "the immune system in patients with peptic ulcer of the duodenum (abdpc) and the influence of modern therapy and immunomodulating agents" Assumerlo, Animalia. //Clinical medicine, 2003, No. 1. - P.40-44. These authors studied the immune status of patients abdpc associated with info is of Helicobacter pylori (HP) infection in the acute phase of the recurrence of the disease in middle-aged men with localized ulcers only in the duodenal bulb. To identify abdpc used the data from the anamnesis, the clinical picture of the disease, esophagogastroduodenoscopy (EGD) with subsequent biopsy of the gastric mucosa (GM). The immune status of patients was evaluated using the test systems: we determined the status of T-and b-systems of immunity (absolute and relative number of T - and b-lymphocytes), the level of immunoglobulins (Ig) 3 main classes of (G, M, a) and indicators of the system of phagocytosis. The research was carried out in dynamics before and after treatment.

In the study of the immune status of patients abdpc revealed a significant impairment of the immune system, characteristic for different severity of secondary immunodeficiencies (VIEW). The observed decrease of the content of a subpopulation of early E-rosette cells, reducing teophelinresistent and definintely E-rosette cells, improved load test with the hormones of the thymus, indicating that the increase in the proportion of immature T cells in the venous blood, reducing the number of b-lymphocytes. The total decrease in the content of T and b immune cells led to increased levels of zero cells in the venous blood. On the background of reducing the total number of b-lymphocytes in the peripheral blood has high levels of IgA and IgM. High show is whether phagocytic activity, and the values of HCT-test was reduced.

To ensure abdc appointed antisecretory agents, mainly from the group of proton pump inhibitor (omeprazole), a complex of 2-3 antibacterial agents, immunomodulating agents (tactivin and immunofan) and vitamin-mineral complex.

After the treatment there was a significant reduction in the activity or the absence of manifestations of chronic gastritis, decreased intensity of lymphoplasmocytic inflammatory infiltration coolant, increased the number bezepitelialnye lymphocytes and infiltration of the mucous membrane of monocytes significantly increased the pH level in all departments of the stomach. Some positive shifts in immune status: normalization of the number of lymphocytes, increased levels of thermostable E-rosette cells, the increase in the absolute number of T-lymphocytes, a decrease in the level of IgA and IgM. Indicators of the functional state of the phagocytic system has not undergone significant changes.

However, the proposed method for the treatment of patients abdpc has, in the opinion of the authors, a number of disadvantages: the treatment was carried out only in patients with localization of ulcers in the duodenal bulb and middle-aged men. Meanwhile, the spectrum EAEPGZ more extensive and involved the t also peptic ulcer, its combination with abdc, chronic erosive gastroduodenal lesions. In addition, the greatest difficulty in treatment are patients of older age groups (both men and women), as these patients are more likely to have reparative processes in the mucous membrane of the gastroduodenal zone, and immune disorders are the most prominent. It should also be noted that at least half of the elderly patients have concomitant hypertension, weight for gastroduodenal pathology, have proposed prototype complex drug when its use has not yielded the desired results.

The authors offer their comprehensive method for the treatment EAEPGZ, combined with hypertension.

The study involved 109 patients predominantly in older age groups (male 62, female 47, the average age of 58.3±2,4 years). Of these, 41 patients were noted EAEPGZ without hypertension (group 1), 68 - EAEPGZ combined with hypertension (group 2). The degree of hypertension was assessed according to the who classification / MOAG (1999), according to which grade I hypertension was observed in 26 (38%) patients, II degree - 18 (28%), grade III - 24 (35%).

Analysis of the peculiarities of the functioning of the immune system and assess the possibility of using immunocorrective medicines in the treatment of patients with EAEPGZ were conducted the following experiments is tion: clinical analysis of blood, determination of the parameters of the immune status test level 1, determination of leukocyte indices. The latter included the leukocyte index (LI), leukocyte index of intoxication (LEII), the index shift of leukocytes (ISL), lymphocytic-granulocyte index (ILG), the index of the ratio of neutrophils and lymphocytes (ISNL), the index of the ratio of neutrophils and monocytes (ISLM), the index of the ratio of lymphocytes and eosinophils (ISLE), lymphocytic intoxication index (LIMII). Determination of leukocyte indices allows more accurate assessment of the immune status of patients and its dynamics. In addition, the assessment of the severity of immune disorders, which resulted in disruption of cellular and humoral immunity, phagocytosis based on modified by the authors of the classification. There were patients who:

1) deviations of the studied parameters of the immune status from the norm was not observed;

2) was observed deviations from the norm qualitative and quantitative parameters of the immune status (risk group HIV);

3) was observed clinical and immunological syndrome characterized by a quantitative decrease in the structural components of the immune system at laboratory examination (group of immunodeficiency).

Patients authors selected 3 degrees of testimontials:

grade 1 - patients with immunodeficiency, which cited the changes 1-2 performance parameters of the immune status of the norm of 20%;

grade 2 - patients with immunodeficiency, which cited the changes 1-2-3 or more indicators of immune status from the norm by 20-50%;

grade 3 - patients with immunodeficiency, which cited the changes 1-2-3 or more parameters of the immune status from the norm by more than 50%.

Studies (table 1) revealed significant differences in the parameters of the immune status in patients EAEPGZ without hypertension (group 1) and with hypertension (group 2).

Table 1

The performance parameters of the immune status in patients EAEPGZ taking into account the presence and absence of AG
Index1-I group, n=412-I group, n=68P
Leukocytes, anti-lock brakesby 5.87±2,245,40±1,56
Stab neutrophils, %2,05±1,403,02±1,790,038
Segmented neutrophils, %54,52±10,6549,62±7,680,016
Eosinophils, %1,66±1,481,96±1,38
BA is Ofili, %0,05±0,280,17±0,62
Monocytes, %8,43±4,376,80±3,48
Lymphocytes,%of 33.26±12,3638,46±8,860,033
The absolute number of lymphocytes1,94±0,591,94±0,54
E-ROCK-lymphocytes, %59,00±8,2754,32±9,71
The absolute number of E-ROCK1,21±0,381,06±0,37
E-ROCK-theophyllinevenlafaxine, %35,67±7,3134,21±8,48
The absolute number of E-ROCK definintely0,66±0,160,67±0,31
E-ROCK teophelinresistent, %23,33±10,8620,11±9,81
Abs. the number of E-ROCK teophelinresistent0,47±0,270,40±0,21
M-ROCK %34,00±12,0738,21±11,070,178
The absolute number of M-ROCK0,64±0,240,75±0,32
O-cells 7,00±8,278,11±9,01
Phagocytic index, 30 min71,83±8,6470,21±14,14
Phagocytic number, 30 min13,33±1,7513,32±1,57
Phagocytic index, 120 min62,50±6,0660,84±15,1B
Phagocytic number, 120 min9,58±1,2814,05±13,86
The coefficient of phagocytic number1,43±0,311,25±0,47
Nst-spontaneous, %61,14±26,95is 47.24±27,650,04
The CCS-spontaneous0,89±0,490,63±0,400,03
Nst-stimulated, %79,11±15,7164,16±16,150,001
The CCS-stimulated1,61±0,701,01±0,450,002
IgA, km13,35±6,8912,90±are 5.36
IgM, Mcm1,55±0,831,52±0,58
IgG, Mcm82,80±22,90the sideways range between 77.90±14,670,02
LI0,69±0,470,82±0,300,02
LEII0,81±0,510,60±0,550,05
ISL1,67±1,261,28±0,460,07
ILG6,38±4,107,42±2,600,05
ISNL3,83±of 10.581,51±0,670,03
ISLM6,36±7,188,93±9,830,09
ISLE22,73±21,42to 21.91±14,62
LIMII0,66±0,450,77±0,280,03

The analysis of the obtained data revealed that patients EAEPGZ with hypertension was observed initially (before treatment) a higher level of immunocompromise. The activity of phagocytosis in patients with EAEPGZ significantly higher than in patients with a combination of EAEPGZ and AG. This is evidenced by the significantly lower values of HCT-spontaneous. There has also been a lower rate of HCT-stimulated, indicating a lower level of efficiency of protection of phagocytic level in patients suffering from EAEPGZ in combination with hypertension. In patients EAEPGZ in combination with hypertension, significantly higher than the concentration of the IgG. This indicates initially lower base level protection system of humoral immunity. Marked activation actually immunocompetent cells. This is evidenced by the increase M-ROCK-lymphocytes, LI, LEII, ISL, ILG, ISNL, ISLM, increasing LIMII in patients suffering from, EAEPGZ in combination with AH.

The data obtained was confirmed by the distribution of patients according to the degree of immune disorders (table 2).

Table 2

The parameters of the immune status of the nature of immune disorders in patients EAEPGZ with the presence and absence of AG (%)
The nature of immune disorders1-I group, n-412-I group, n=68
Patients with no immune disorders0 (0%)0 (0%)
Patients with risk immunodeficiency33 (80%)45 (66%)
Patients with immunodeficiency8 (20%)23 (34%)
Total:41 (100%)68 (100%)

As the results of the studies (table 2), all patients with EAEPGZ there are different variants of immune disorders. However, most pronounced immune disorders was combined for EAEPGZ and And the. Thus, the majority of patients in both groups were observed immunodeficiency 1 severity, rarely met 2 degrees in the absence of a 3 degree of immunodeficiency. When combined EAEPGZ with AG immunodeficiency 2 degrees was observed more frequently than in patients EAEPGZ without AG, respectively, in 10 (15%) and 2 (5%) cases. This confirms that the presence of hypertension in patients EAEPGZ is a factor, in addition impair the immune system.

In both groups (EAEPGZ without AG and AG) patients were used as basic therapy, including H. pylori tools and vitamin-mineral complex. Basic therapy was supplemented by the appointment of immunomodulators. However, if the 1st group patients achieved significant clinical and endoscopic and laboratory improvement, in patients of the 2nd group with sufficient effectiveness of the treatment is not received. This is due, as noted, with a worsening of the current EAEPGZ when AH and more significant disruption of the immune system in these patients. Given this, it is necessary to carry out treatment EAEPGZ taking into account the severity of hypertension.

Therefore, the applicants proposed a new complex combination therapy in patients EAEPGZ with hypertension. Combination therapy includes basic therapy, immunocorrective medical complex, anti-hypertensive therapy.

Basic care is:

1) antisecretory drug omeprazole 20 mg 2 times a day;

2) antibiotic amoxicillin 1,0 2 times a day;

3) antibacterial drug furazolidone 0.1 to 3 times a day.

Course basic (H. pylori) treatment was carried out for 7 days with subsequent continuation of omeprazole 2-3 weeks on the same dose with dose reduction to 20 mg 1 time a day for 4 weeks.

Immunocorrective complex:

1) Likopid of 0.005 to 1 times a day, 10 days;

2) Vetoron TC 1 capsule per day for 20 days;

3) Cortexin 10 mg/m in 5 ml of physiological solution 1 once a day for 10 days.

Likopid appointed in connection with the fact that patients noted a marked lack of phagocytic activity level, and Likopid is an immunomodulator, which is primarily aimed at activation of phagocytosis. This allows you to enhance the process of presentation of antigenic material, and, in addition, strengthen the process of cooperation with immunocompetent cells. Thus the conditions for better elimination of antigenic material from the body.

Cortexin introduced in the course of treatment, given the important role of the Central nervous system in the pathogenesis of hypertension and EAEPGZ. Cortexin helps normalize the activity of the Central nervous system, regulation of vascular tone that p is igodit to increase the effectiveness of treatment as AG, and EAEPGZ.

Vetoron TC appointed taking into account the presence in its composition of antioxidants. Introduction in the complex of therapeutic treatment reduces the inflammatory process in the gastroduodenal area and creates opportunities to increase the effectiveness of remedial measures.

Antihypertensive therapy for hypertension I-II degree included, as a rule, 1-2 hypotensive drugs - diuretics or ACE inhibitors, or beta blockers, or calcium antagonists in conventional doses. When AG III degree - combined antihypertensive therapy 2-3 drugs listed above.

As a result of the treatment of the above combined complex patients EAEPGZ with hypertension there was a significant positive trend as clinical and endoscopic parameters, and parameters of the immune status. At the end of therapy, all patients were eliminated pain, dyspepsia was absent or significantly decreased. All patients had happened epithelialization of the ulcer, but some of them continued erosion in the stomach and/or duodenum with signs of inflammation of the gastroduodenal zone. It was found that the deterioration or lack of positive dynamics of clinical and endoscopic data in patients EAEPGZ (prolonged period of pain and spacechecker syndromes long-term scarring ulcers, lack of complete epithelization of erosions in the stomach and duodenum) depended on the degree of concomitant hypertension, increases in frequency with increasing degree (from I to III).

As for the dynamics parameters of the immune status in patients with EAEPGZ with hypertension after treatment, it was expressed in the following: improvement of 42 (62%) patients, no significant dynamics, 18 (26%), deterioration - 8 (12%). Analysis of the obtained data has shown that this dynamics depended on the degree of hypertension (table 3).

Table 3

Dynamics parameters immunolabeling indicators in patients EAPGJ with hypertension depending on the degree of hypertension, (%)
IndexEAEPGZ with I-II degree of AG, n=44EAEPGZ with III degree of hypertension,

n=24
Improvement32 (74%)10 (42%)
No significant dynamics9 (20%)9 (38%)
Deterioration3 (6%)5 (20%)
Total:44 (100%)24(100%)

As shown by the results of the studies (table 3), III-degree of hypertension was noted less favourable dynamics of the immune status than with hypertension I-II degree. This was confirmed and the data distribution of patients according to the degree of Munich disorders (table 4).

Table 4

The parameters of the immune status of the nature of immune disorders in patients EAEPGZ depending on the degree of concomitant hypertension, %
The nature of immune disordersEAEPGZ with I-II degree of AG, n=44EAEPGZ with III degree of AG, n=24
Patients with no immune disorders5 (11%)0 (0%)
Patients with risk immunodeficiency37 (83%)17 (71%)
Patients with immunodeficiency2 (6%)7 (29%)
Total:44 (100%)24 (100%)

In addition, patients suffering from EAEPGZ in combination with hypertension I-II degree, after treatment was noted immunodeficiency only 1 severity, and EAEPGZ with AG III level 3 patients (12%) patients reported immunodeficiency 1 severity, and 4 (17%), immunodeficiency, 2 severity. This indicates a lower efficiency of treatment of patients EAEPGZ with AG III degree and want to optimize ongoing therapeutic measures.

Have analyzed changes in clinical and endoscopic findings in patients EAEPGZ with III degree of AG after the combined treatment. It turned out that full clinical-endoscopies the second remission was not obtained in all patients with deterioration of immune status and in 4 out of 9 - with the absence of positive dynamics. Among these patients, 6 patients were immunocompromised and 3 - with the risk of its development. These patients (9 patients) was extended course immunocorrective therapy application superlymph.

The lack of significant positive dynamics was noted in patients with uncontrolled hypertension, which was characterized by the presence of multiple or multiple ulcers on the background of erosive lesions of the mucous membrane of the stomach and/or duodenum and was expressed by the deterioration of parameters of the immune status of incomplete clinical remission with preservation of erosive inflammatory changes in the mucosa of the gastroduodenal zone.

The authors recommend to Supplement the scheme immunocorrective effects in patients with combination EAEPGZ and AG III degree the purpose of the immunomodulator superlymph, which is applied topically on the area of the ulcer and erosive lesions. First and foremost, it is expedient, since patients suffering from EAEPGZ with AG III, noted the pronounced state of immunocompromise with damage to different parts of the immune system and significant local changes in the area of the ulcer and erosive effects. In this regard, the authors have increased the course of treatment additional appointment immunomodulating drug is about money locally, possessing additionally the ability to enhance the repair of damaged tissues. Superlymph is necessary to achieve this property.

Immunomodulator superlymph was used (100 μg dry matter dissolved in 3-5 ml of 0.9% saline solution) 1 times a day with an interval of 4-5 days in the amount of 3-4 treatments, topically (through the endoscope) in the amount of 3-5 ml for 1 irrigation, depending on the irrigated surface.

A comparative analysis of the effectiveness of interventions in patients with a combination of EAEPGZ and AG III degree with combined therapy and combination therapy, supplemented by appointment superlymph. It turned out that patients with EAEPGZ and III degree of hypertension treated with supplemented combination therapy clinical-endoscopic and immunological improvement occurred in 7 (78%) cases, no significant change in 2 (22%).

Obvious advantages of the proposed integrated method of treatment EAEPGZ, combined with hypertension are:

the purpose of the immunomodulator licopid aimed at activation of phagocytosis, which allows you to accelerate the presentation of antigenic material, and, in addition, enhances cooperation with immunocompetent cells;

the purpose of Cortexin has a beneficial effect on the treatment EAEPGZ through IU Balicasag and neuroprotective effects and treatment of hypertension due to neuroprotective and cerebroprotective effects;

- assign veteran TC, which is an antioxidant that helps to reduce the inflammatory process of the mucous membranes of the gastrointestinal tract;

the purpose of the immunomodulator superlymph applied topically to the area of erosive and ulcerative defects in the mucosa of the gastroduodenal zone, stimulates phagocytosis, enhances the repair of tissue reconstruction of the defect without the formation of unsightly scars. Superlymph especially indicated in cases of insufficient effectiveness of treatment EAEPGZ, which is typical when combined AG III degree;

- the combined use of the two immunomodulators licopid and superlymph shown in connection with the fact that Likopid activates phagocytosis system primarily systemic and superlymph locally at the level of the ulcer and erosive defect, thus increasing repair damaged tissues;

- offer a range of combination therapy, including Likopid, Cortexin, Vetoron TC, supplemented by superlymph allows you to reach the vast majority of patients EAEPGZ when combined with hypertension optimal treatment results in a relatively short time.

Clinical example # 1:

Patient P., 61-year history No. 2130. Diagnosis: Chronic erosive gastroduodenitis in the acute stage. Arterial hypertension of I degree, the risk of developing cardiovascular is slojneni - 3.

Treatment: omeprazole 20 mg 2 times a day, amoxicillin 1,0 2 times a day, furazolidone 0.1 to 3 times a day, Likopid 0,005 1 time per day under the tongue 10 days, Cortexin 10 mg 1 time per day intramuscularly for 10 days, Vetoron TC 1 capsule per day for 20 days, Enap 10 mg 1 time per day.

Table 5
Indicator of immune statusBefore the treatmentAfter treatment after 3 weeks
Leukocytes, anti-lock brakes4,85,1
Stab neutrophils, %2,00,5
Segmented neutrophils, %33,043
Eosinophils, %3,07
Basophils, %0,00
Monocytes, %7,012
Lymphocytes, %55,038,0
The absolute number of lymphocytes2,64is 3.08
E-ROCK-lymphocytes, %5272
The absolute number of E-ROCK1,372,22
E-ROCK-theophyllinevenlafaxine, %2425
The absolute number of E-ROCK for those who villenouvelle 0,630,74
E-ROCK teophelinresistent, %2848
Abs. the number of E-ROCK teophelinresistent0,741,48
M-ROCK %4810
The absolute number of M-ROCK1,270,31
O-cells018
Phagocytic index, 30 min4580
Phagocytic number, 30 min1014
Phagocytic index, 120 min6595
Phagocytic number, 120 min1415
The coefficient of phagocytic number0,710,93
Nst-spontaneous, %325
The CCS-spontaneous0,440,05
Nst-stimulated, %4357
The CCS-stimulated0,660,74
IgA, CMY1828
IgM, Mcm1,91,6
IgG, Mcm133110
LI1,70,9
0,150.4
ISL0,611,0
ILG14,07,5
ISNL0,61,4
ISLM7,83,2
ISLE18,3of 5.4
LIMII1,60,9

As a result of therapy noted positive dynamics of clinical - complete relief of pain and dyspeptic syndromes, parameters of the immune status of complete epithelialization of erosions in the stomach and duodenum in 3 weeks.

Clinical example 2:

Sick Hours, 55 years old, medical history, No. 2343. The diagnosis of peptic Ulcer disease duodenal ulcer in the acute stage. Chronic erosive gastroduodenitis in the acute stage. Hypertension III degree, the risk of development of cardiovascular complications - 4.

Treatment: omeprazole 20 mg 2 times a day, amoxicillin 1,0 2 times a day, furazolidone 0.1 to 3 times a day, Likopid 0,005 1 time per day under the tongue 10 days, Cortexin 10 mg 1 time per day intramuscularly, Vetoron TC 1 capsule per day for 20 days, superlymph was applied 2 times per week for 2 weeks, topically, endoscopically in the amount of 4 ml for 1 irrigation, Enap 20 mg 2 times a day, arifona table 1 the TKA in the day.

tr>
Table 6
Indicator of immune statusBefore the treatmentAfter treatment after 3 weeks
Leukocytes, anti-lock brakesa 4.95,3
Stab neutrophils, %103
Segmented neutrophils, %5749
Eosinophils, %35
Basophils, %02
Monocytes, %38
Lymphocytes, %2733
The absolute number of lymphocytes1,321,75
E-ROCK-lymphocytes, %4868
The absolute number of E-ROCK0,631,09
E-ROCK-theophyllinevenlafaxine, %2628
The absolute number of E-ROCK definintely0,340,49
E-ROCK teophelinresistent, %2234
Abs. the number of E-ROCK teophelinresistent0,290,60
M-ROCK %2810
The absolute number of M-ROCK0,370,18
O-cells2428
Phagocytic index, 30 min4574
Phagocytic number, 30 min1314
Phagocytic index, 120 min6262
Phagocytic number, 120 min1410
The coefficient of phagocytic number0,931,4
Nst-spontaneous, %4628
The CCS-spontaneous0,720,36
Nst-stimulated, %7771
The CCS-stimulated1,141,11
IgA, km1223
IgM, Mcm1,20,86
IgG, Mcm91109
LI0,470,67
LEII0,60,2
ISL2,31,4
ILGa 3.95,8
ISNL2,51,6
ISLM94,1
ISLE 96,6
LIMII0,40,6

As a result of the course of therapy, the positive dynamics of the clinical picture (complete relief of pain and dyspeptic syndromes), the positive dynamics of parameters of immune status. On the control EGDS (4 weeks) duodenal ulcer healed and fully epithelialize erosion.

1. A method of treating ulcer and erosive gastroduodenal lesions, combined with arterial hypertension, characterized in that make the clinical analysis of blood, determine leukocyte indexes - leukocyte index (LI), leukocyte index of intoxication (LEII), the index shift of leukocytes (ISL), lymphocytic-granulocyte index (ILG), the index of the ratio of neutrophils and monocytes (ISLM), the index of the ratio of lymphocytes and eosinophils (ISLE), lymphocytic intoxication index (LIMII), determine the parameters of the immune status, leukocyte indexes estimate the dynamics parameters of the immune status and patients the ulcer and erosive gastroduodenal lesions zone in combination with arterial hypertension I-St and II-nd degree, with the presence of immune disorders prescribed anti-hypertensive medications and combined together with immunomodulating therapy, including Likopid, Cortexin and Vetoron TC, and the combination with arterial hypertension III-rd degree appoint immunomodulator superlymph.

2. The method of treatment according to claim 1, characterized in that Likopid appoint 0,005 1 time a day for 10 days.

3. The method of treatment according to claim 1, characterized in that Cortexin administered intramuscularly in a dose of 10 mg 1 time a day for 10 days.

4. The method of treatment according to claim 1, characterized in that Vetoron TC prescribed 1 capsule per day for 20 days.

5. The method of treatment according to claim 1, characterized in that it further introduce a solution superlymph locally, endoscopically on the area of the ulcer and erosive lesions of 1 times a day with an interval of 4-5 days in the amount of 3-4 treatments at the rate of 100 µg of dry matter per 5 ml of 0.9 percent saline solution for 1 irrigation.



 

Same patents:

FIELD: organic chemistry, madicine.

SUBSTANCE: tricyclic benzodiazepines of formula I as well as their pharmaceutical acceptable salts, pharmaceutical composition containing the same and methods for hypertension treatment are disclosed. In formula A is -C(O)-; Y is CH2 or CH as olefinic site; X is CH2 or CH as olefinic site S, O or NR3 (R3 is C1-C8-alkyl) with the proviso that when Y is CH, X also is CH; Z is N or CH; R1 is hydrogen, C1-C8-alkyl, C1-C8-alkoxy or halogen; R2 is NR4COAr (R4 is hydrogen; Ar is phenyl optionally substituted with 1-3 substitutes independently selected from C1-C8-alkyl, halogen, hydroxyl, fluorinated C1-C8-alkylthio and another phenyl optionally substituted with substitute selected from C1-C4-alkyl, halogen, and hydroxyl); R5 is hydrogen, C1-C4-alkyl, C1-C4-alkoxy, fluorine, chlorine, hydroxyl or di-(C1-C4)-alkylamino.

EFFECT: improved pharmaceutical composition for hypertension treatment.

12 cl, 5 tbl, 52 ex

FIELD: medicine.

SUBSTANCE: method involves administering Noliprelum in postoperative period for reducing left ventricle hypertrophy.

EFFECT: enhanced effectiveness of treatment in early postoperative period.

FIELD: medicine, endocrinology, pharmacology, pharmacy.

SUBSTANCE: invention relates to a pharmaceutical combined composition used for treatment or prophylaxis of hypertension in patients suffering with diabetes mellitus. The composition comprises AT1-antagonist valsartan or its pharmaceutically acceptable salt and calcium channel blocking agent or its pharmaceutically acceptable salt, and pharmaceutically acceptable carrier. The composition elicits synergistic effect and expanded spectrum effect.

EFFECT: improved and valuable medicinal properties of composition.

10 cl, 3 tbl

The invention relates to pharmaceutical industry and relates to pharmaceutical compositions containing 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid or 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate, to prevent, treatment or inhibition of the development of a simple retinopathy or preproliferative retinopathy; the method of preventing, treating or inhibiting the development of a simple retinopathy or preproliferative retinopathy; and applying the 2-ethoxy-1-[[2'-(1 N-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid or 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]the benzimidazole-7-carboxylate

The invention relates to medicine, in particular to pharmaceutical compositions containing the blocker of calcium and pharmacologically acceptable alkaline material, which is added in an amount such that the aqueous solution or dispersion solution of a specified pharmaceutical compositions containing a blocker of calcium, would have a pH of at least 8

The invention relates to new 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-triptoreline)-benzyl)aminocarbonylmethyl)-2-(4-terbisil)thio-5,6-trimethylene-pyrimidine-4-ONU formula (I):

or its pharmaceutically acceptable salts, which have the properties of inhibitors of the enzyme Lp-PLA2and can be used to treat or prevent a painful condition associated with the activity of the specified enzyme

The invention relates to new nitrogen-containing aromatic 6-membered cyclic compounds of the formula (I) or their pharmaceutically acceptable salts, demonstrating excellent selective PDE V inhibitory activity

The invention relates to the processing of reindeer products, in particular to a method for producing a biologically active extract of tinned tails deer antler

The invention relates to an improved method of producing benzosulfimide amlodipine, which is also known as besilate amlodipine and has the full chemical name-bansilalpet 3-ethyl-5-methyl ester 2-[(2-aminoethoxy)methyl] -4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid, which is valuable antiischemic and antihypertension connection

FIELD: medicine, gastroenterology.

SUBSTANCE: invention relates to a method for prophylaxis of relapses of stomach and duodenum ulcer disease. Method involves using 3-(2,2,2-trimethylhydrazinium)-propionate dihydrate and novocain that are given by oral route simultaneously. The medicine 3-(2,2,2-trimethylhydrazinium)-propionate dihydrate is administrated in the dose 200-240 mg, twice per a day and novocain is given in the dose 10-12 mg, twice per a day for 12-15 days in spring-autumn periods. Method normalizes secretory and bioelectric activity of stomach and provides effectiveness for prophylaxis of disease.

EFFECT: improved and enhanced method for prophylaxis.

3 ex

FIELD: medicine, combustiology, surgery.

SUBSTANCE: one should apply monotherapy with ecdisterone solution in olive oil at concentration of 0.001-0.01% to be introduced per 10 ml thrice daily after meals for 10-14 d. The present innovation shortens terms of therapy in [patients with the above-mentioned nosology due to more rapid epithelization of esophageal mucosa.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: medicine, gastroenterology, pharmacy.

SUBSTANCE: invention relates to a solid composition eliciting with an anti-ulcer activity and to a method for its preparing. Pharmaceutical composition consists of a core containing famotidine as an active component and starch, aerosil, stearic acid salt as accessory inert substances wherein a core is covered by polymeric envelope. Core comprises glucose and stearic acid as an accessory inert substance and magnesium stearate as a stearic acid salt. Polymeric envelope comprises oxypropylmethylcellulose, propylene glycol, castor oil, talc and titanium dioxide taken in the definite ratio of all components in the composition. Method for preparing pharmaceutical composition involves preparing raw, mixing therapeutically effective amount of famotidine with glucose and starch, moistening the mixture with starch paste, granulation, drying wetted granulate, repeated granulation, powdering dry granules, tableting and applying polymeric envelope containing oxypropylmethylcellulose on prepared cores with addition of titanium dioxide, propylene glycol, castor oil and talc. Invention provides enhancement of degradability, solubility and stability in storing.

EFFECT: improved method for preparing, valuable pharmaceutical properties of composition.

3 cl, 1 ex

FIELD: medical virology and microbiology.

SUBSTANCE: new bacteriophage strain Helicobacter pylori, having lytic activity is disclosed. Method for production of antigastritis and antiulcer drug based on the new bacteriophage strain also is disclosed. Claimed method includes providing of purified suspension of bacteriophage Helicobacter pylori with lytic activity of 109 FFU/ml and addition of 1 % chinozole thereto. Moreover sorbitole and gelatose also may be introduced into said agent. Obtained mixture is frozen and lyophilized.

EFFECT: high effective antigastritis and antiulcer drug useful in medicine.

3 cl, 1 tbl, 2 ex

FIELD: gastroenterology.

SUBSTANCE: eradication of infection Heliobacter pylory in stomach comprises oral administration of corresponding drugs in powdered form mixed with orange juice. In particular, mixture of colloidal bismuth subcitrate (De-nol), Nifuratel (Macmirror), and Amoxycyllin (Flemoxin solutab) are used. Administration is performed on an empty stomach at least 30-40 min before the food intake. Patient then lies at least 30 min on the both sides alternatively.

EFFECT: suppressed water-repellent property of near-wall layer of stomach mucus and slowed down evacuation of liquid from stomach thereby ensuring fast diffusion of therapeutical substances into infect persisting zone and, therefore, direct bactericidal effect on Heliobacter pylory.

4 cl

FIELD: medicine.

SUBSTANCE: peptide of the following formula: X-Pro-Gly-P, where X = Thr-Lys-Pro-Arg-; Lys-pro-Arg-; pro-Arg-; Arg-, being of untiulcerous activity. They should be applied at intraperitoneal injection at the dosage of 0.58-3.20 mcM g/kg for preventing and treating ulcers of gastro-intestinal tract.

EFFECT: higher efficiency and prophylaxis.

4 dwg, 5 ex

FIELD: medicine, gastroenterology.

SUBSTANCE: traditional eradication therapy should be supplemented with licopid at the dosage of 10 mg per os once daily before breakfast for 10 d. The present innovation prevents transfer of microorganisms into inactive form, accelerates restoration of mucosal epithelial layer in gastroduodenal area, provides complete eradication of microorganisms, that in its turn, favors to prevent disease exacerbation and restoration of gastroduodenal functions.

EFFECT: higher efficiency of therapy.

3 dwg, 2 ex

FIELD: pharmaceutics.

SUBSTANCE: the present innovation deals with peroral liquid compositions which could be designed into gelatinous capsules. The suggested pharmaceutical composition includes a pharmaceutically active agent, a solubilizing agent and, not obligatory, a surface-active substance and a plastifying agent. The pharmaceutically active agent has got, at least, one acidic fragment, preferrably, that of carbonic acid being chosen out of the group of non steroid antiphlogistic preparations being acid-soluble at acid : dissolved substance ratio being from 3:1 to 10000:1. New compositions provide increased rates and degrees of absorption of pharmaceutically active agent and minimize side effects caused by such active substances.

EFFECT: higher efficiency of application.

42 cl, 39 ex

FIELD: medicine.

SUBSTANCE: method involves applying eradicative anti-helicobacterial therapy comprising Omeprazol administration at a dose of 20 mg twice a day and Ximedone at a dose of 500 mg twice a day in 12 days long course.

EFFECT: enhanced effectiveness of eradication; reduced adverse side effects risk.

FIELD: medicine, gastroenterology.

SUBSTANCE: invention relates to methods for treatment of chronic helicobacter pylori-associated gastritis. Method is carried out by monotherapy with the probiotic "Laminolakt" in the dose 3 dragees per 24 h for 1 month. Method provides elimination of Helicobacter pylori cells on the background of activation of the immune response in stomach mucosa by effect on microflora and the colon intestine immune system.

EFFECT: enhanced effectiveness of treatment.

2 tbl, 1 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to an agent with broad spectrum of biological effect. Agent based on natural interferon and/or recombinant interferon of α- and/or β- and/or γ-types. Agent is made in the form of different medicinal formulations and elicits immunomodulating, antibacterial, antioxidant and regenerating effect and designated for both internal using and external applying on skin and mucosa tissues. Invention provides the development of medicinal agent with broad spectrum of biological action. The prolonged administration of preparation doesn't effect on morphological composition of peripheral blood and has no effect on blood coagulation. The preparation doesn't show topical irritation and pyrogenic effect.

EFFECT: valuable medicinal properties of agent.

22 cl, 8 ex

Up!